Does Lurbinectedin Harm a Developing Fetus?
Lurbinectedin (Zepzelca), approved for small cell lung cancer, carries significant risks during pregnancy. It is classified as Pregnancy Category D by the FDA, meaning animal studies show fetal harm and human risks outweigh benefits, though controlled studies in pregnant women are absent.[1] Nonclinical data reveal embryofetal toxicity: in rats and rabbits, doses around human equivalents caused post-implantation loss, decreased fetal weight, skeletal variations, and malformations like fused vertebrae or missing tail. No viable offspring survived to term at higher exposures.[2]
What Happens If Taken During Pregnancy?
Human data is limited to case reports, but the drug's mechanism—binding DNA and inhibiting cell division—targets rapidly dividing fetal cells, raising teratogenic risks similar to other alkylating agents. Women exposed during pregnancy face miscarriage, birth defects, or fetal death. The prescribing label warns of potential fetal harm and mandates contraception for women of reproductive potential during treatment and for 6 months after.[2]
Pregnancy Testing and Contraception Rules
Before starting lurbinectedin, verify pregnancy status via test. Females must use effective non-hormonal contraception (e.g., IUD, barrier methods) during therapy and 6 months post-dose; hormonal options alone are insufficient due to enzyme induction risks. Males should use condoms during treatment and 4 months after, even with non-pregnant partners.[2]
Breastfeeding Risks After Treatment
Do not breastfeed during lurbinectedin use and for 1 week after the last dose. It and its metabolites pass into milk in animal models, potentially harming infants via gastrointestinal absorption or blood levels.[2]
Alternatives for Pregnant Cancer Patients
No direct substitutes exist for pregnant women with small cell lung cancer, but options like supportive care or less toxic chemotherapies (e.g., etoposide-platinum regimens) may be considered after risk-benefit assessment. Consult oncology and maternal-fetal medicine specialists; clinical trials exclude pregnant patients.[3]
[1] FDA Label for Zepzelca (lurbinectedin), https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[2] Zepzelca Prescribing Information, Jazz Pharmaceuticals, embryofetal toxicity section
[3] NCCN Guidelines for Small Cell Lung Cancer, Version 3.2023 (pregnancy considerations)